Recombinant SARS-CoV-2 Spike His Protein, CF
Recombinant SARS-CoV-2 Spike His Protein, CF Summary
Why choose R&D Systems SARS-CoV-2 Spike Protein?
- Val16-Lys1211 with a C-term His tag.
- Stabilizing mutations K986P and V987P promote the prefusion conformation.
- Two mutations, R682S and R685S, eliminate a Furin protease cleavage site.
- Guaranteed Bioactivity and High Purity: Bioactivity tested by functional ELISA and purity determined by SDS-PAGE to be greater than 95%.
- Lot-to-Lot Consistency: Stringent QC testing performed on each lot to ensure consistent activity and purity.
- Bulk Quantities Available: Bulk up and save with large mass quantities to meet your research needs. Supply agreements available, partner with us. Please contact us.
- Most Respected, Most Cited Brand in Proteins: With over 35 years of providing the best recombinant proteins to the scientific community, R&D Systems continues to lead the industry in quality, activity, and purity.
Interested in other Coronavirus proteins including SARS-CoV-2 Spike proteins? View Products
Product Specifications
Val16-Lys1211 (Arg682Ser, Arg685Ser, Lys986Pro and Val987Pro) with a C-terminal 6-His tag
Suitable for use in serological assay development
Analysis
Product Datasheets
10549-CV
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
10549-CV
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
| Reconstitution | Reconstitute at 500 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
View Larger
2 μg/lane of Recombinant SARS-CoV-2 Spike His Protein (10549-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 144-175 kDa.
View Larger
Recombinant SARS-CoV-2 Spike His Protein (Catalog # 10549-CV) was immobilized on a Biacore Sensor Chip CM5, and binding to recombinant human ACE-2 (Catalog # 933-ZN) was measured at a concentration range between 0.37 nM and 93.5 nM. The double-referenced sensorgram was fit to a 1:1 binding model to determine the binding kinetics and affinity, with an affinity constant of KD=1.720 nM.
View Larger
SDS-PAGE of 1 µg of R&D Systems Recombinant SARS-CoV-2 Spike (10549-CV) or a competitor’s Spike protein were run under reducing or non-reducing conditions and visualized by silver staining. The R&D Systems Spike protein runs as a single band compared to the competition.
View Larger
In a functional flow cytometry test, (A) Recombinant SARS-CoV-2 Spike His-tag Protein (Catalog # 10549-CV) binds to HEK293 human embryonic kidney cell line transfected with recombinant human ACE-2 and EGFP. Ligand binding was detected by staining cells with APC-conjugated anti-His Monoclonal Antibody (IC050A), which does not stain the cells in the absence of recombinant protein (B).
Background: Spike
SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into the S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). The S protein of SARS-CoV-2 shares 75% and 29% amino acid (aa) sequence identity with the S protein of SARS-CoV-1 and MERS, respectively.The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds Angiotensin-Converting Enzyme 2 (ACE2), but with much higher affinity and faster binding kinetics through the receptor binding domain (RBD) located in the C-terminal region of S1 (6). Based on structural biology studies, the RBD can be oriented either in the up/standing or down/lying state with the up/standing state associated with higher pathogenicity (7). Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (8). It has been demonstrated that the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (9, 10). A SARS-CoV-2 variant carrying the S protein aa change D614G has become the most prevalent form in the global pandemic and has been associated with greater infectivity and higher viral load (11, 12).
- Wu, F. et al. (2020) Nature 579:265.
- Tortorici, M.A. and D. Veesler (2019). Adv. Virus Res. 105:93.
- Bosch, B.J. et al. (2003). J. Virol. 77:8801.
- Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871.
- Millet, J.K. and G.R. Whittaker (2015) Virus Res. 202:120.
- Ortega, J.T. et al. (2020) EXCLI J. 19:410.
- Yuan, Y. et al. (2017) Nat. Commun. 8:15092.
- Tai, W. et al. (2020) Cell. Mol. Immunol. https://doi.org/10.1016/j.it.2020.03.007.
- Wang, X. et al. (2020) https://doi.org/10.1038/s41423-020-0424-9.
- Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.
- Korber, B. et al. (2020) Cell 182, 812.
- Zhang, L. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.06.12.148726v1.
Citations for Recombinant SARS-CoV-2 Spike His Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
13
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency
Authors: McGee, JE;Kirsch, JR;Kenney, D;Cerbo, F;Chavez, EC;Shih, TY;Douam, F;Wong, WW;Grinstaff, MW;
Nature biotechnology
Species: N/A
Sample Types: Antibody
Applications: ELISA Capture -
Potent neutralization by a receptor binding domain monoclonal antibody with broad specificity for SARS-CoV-2 JN.1 and other variants
Authors: Piepenbrink, MS;Khalil, AM;Chang, A;Mostafa, A;Basu, M;Sarkar, S;Panjwani, S;Ha, YH;Ma, Y;Ye, C;Wang, Q;Green, TJ;Kizziah, JL;Erdmann, NB;Goepfert, PA;Liu, L;Ho, DD;Martinez-Sobrido, L;Walter, MR;Kobie, JJ;
bioRxiv : the preprint server for biology
Species: N/A
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance (SPR) -
Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history
Authors: Kiszel, P;Sík, P;Miklós, J;Kajdácsi, E;Sinkovits, G;Cervenak, L;Prohászka, Z;
Scientific reports
Species: Human
Sample Types: Recombinant Protein
Applications: ELISA Capture -
Evidence, detailed characterization and clinical context of complement activation in acute multisystem inflammatory syndrome in children
Authors: G Sinkovits, J Schnur, L Hurler, P Kiszel, ZZ Prohászka, P Sík, E Kajdácsi, L Cervenak, V Maráczi, M Dávid, B Zsigmond, É Rimanóczy, C Bereczki, L Willems, EJM Toonen, Z Prohászka
Scientific Reports, 2022-11-17;12(1):19759.
Species: Human
Sample Types: Recombinant Protein
Applications: ELISA Standard -
An experimental test of the nicotinic hypothesis of COVID-19
Authors: NE Godellas, GD Cymes, C Grosman
Proceedings of the National Academy of Sciences of the United States of America, 2022-10-24;119(44):e2204242119.
Species: Human
Sample Types: Protein
Applications: Control -
Calcium dobesilate reduces SARS-CoV-2 entry into endothelial cells by inhibiting virus binding to heparan sulfate
Authors: Y Kiyan, A Schultalbe, E Chernobriv, S Tkachuk, S Rong, N Shushakova, H Haller
Scientific Reports, 2022-10-07;12(1):16878.
Species: Human
Sample Types: Recombinant Protein
Applications: Bioassay -
Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months
Authors: CS Lea, K Simeonsson, AM Kipp, C McNeill, L Wilcox, W Irish, H Morris, OM Diaz, JT Fallon, RL Roper
Vaccines, 2022-09-15;10(9):.
Species: Human
Sample Types: Serum
Applications: ELISA Capture -
SARS-CoV-2 Spike Proteins and Cell-Cell Communication Inhibits TFPI and Induces Thrombogenic Factors in Human Lung Microvascular Endothelial Cells and Neutrophils: Implications for COVID-19 Coagulopathy Pathogenesis
Authors: B Bhargavan, GD Kanmogne
International Journal of Molecular Sciences, 2022-09-09;23(18):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay -
Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
Authors: MS Piepenbrin, JG Park, A Deshpande, A Loos, C Ye, M Basu, S Sarkar, AM Khalil, D Chauvin, J Woo, P Lovalenti, NB Erdmann, PA Goepfert, VL Truong, RA Bowen, MR Walter, L Martinez-S, JJ Kobie
PloS Pathogens, 2022-07-21;18(7):e1010691.
Species: Primate - C. aethiops
Sample Types: Whole Cells
Applications: Surface Plasmon Resonance -
Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination
Authors: ES Geanes, C LeMaster, ER Fraley, S Khanal, R McLennan, E Grundberg, R Selvaranga, T Bradley
Scientific Reports, 2022-04-20;12(1):6496.
Species: Human
Sample Types: Serum
Applications: ELISA Capture -
Humoral Immunogenicity and Reactogenicity of the Standard ChAdOx1 nCoV-19 Vaccination in Taiwan
Authors: JH Chang, JF Chiou, CS Hung, MC Liu, HW Chang, SY Hong, CY Wang, YL Lin, YC Hsieh, CL Chung, YS Su, SS Hsiao, D Liu, JJ Liang, CC Liao, CS Chang, KS Lai, HC Chuang, KL Chien, WC Wu, YG Lee, SE Lin, YK Shen, CF Hsu, JC Wang, SH Hsiao
Vaccines, 2022-02-17;10(2):.
Species: Human
Sample Types: Serum
Applications: ELISA Capture -
The spike protein of SARS-CoV-2 induces endothelial inflammation through integrin alpha5beta1 and NF-kappaB signaling
Authors: JP Robles, M Zamora, E Adan-Castr, L Siqueiros-, G Martinez d, C Clapp
The Journal of Biological Chemistry, 2022-02-07;0(0):101695.
Species: Human, Mouse, Rat
Sample Types: In Vivo, Recombinant Protein
Applications: Bioassay, In Vivo -
Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein
Authors: E Jover, L Matilla, M Garaikoetx, A Fernández-, P Muntendam, F Jaisser, P Rossignol, N López-Andr
Biomedicines, 2021-06-03;9(6):.
Species: Human
Sample Types: Whole Cells
Applications: Bioassay
FAQs
-
What is the strain of 10549-CV?
10549-CV is the wild-type Wuhan strain, and the NCBI reference sequence from Accession # YP_009724390.1 identifies the strain (https://www.ncbi.nlm.nih.gov/protein/YP_009724390.1).
Reviews for Recombinant SARS-CoV-2 Spike His Protein, CF
Average Rating: 5 (Based on 4 Reviews)
Have you used Recombinant SARS-CoV-2 Spike His Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Reason for Rating: Worked great for in vitro challenge against THP-1 cells.
Reason for Rating: Good consistent and reliable results for my binding ELISA assay
